Correction: Effect of bisphosphonate use on risk of postmenopausal breast cancer: Results from the randomized clinical trials of alendronate and zoledronic acid (JAMA Internal Medicine (2014) 174, 10 (1551-1558) DOI: 10.1001/jamainternmed.2014.3634);Effect of bisphosphonate use on risk of postmenopausal breast cancer: Results from the randomized clinical trials of alendronate and zoledronic acid

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1550-1557

  Hue, Trisha F ^a   Cummings, Steven R ^a,b   Cauley, Jane A ^c   Bauer, Douglas C ^a   Ensrud, Kristine E ^d   Barrett Connor, Elizabeth ^e   Black, Dennis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; IPRIFLAVONE; MEDROXYPROGESTERONE ACETATE; PLACEBO; PRASTERONE; RALOXIFENE; TAMOXIFEN CITRATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FEMUR NECK FRACTURE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MINERAL SUPPLEMENTATION; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; VITAMIN SUPPLEMENTATION; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PAGET NIPPLE DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INCIDENCE; INFUSIONS, INTRAVENOUS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; RISK;

EID: 84907963939     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5554     Document Type: Erratum

References (50)

1. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15(11):2211-2221.
2. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 2007;246(1-2):308-312.
3. Gnant M, Mlineritsch B, SchippingerW, et al; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
4. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188-2194.
5. Gnant M, Mlineritsch B, Stoeger H, et al; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12 (7):631-641.
6. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398-405.
7. Coleman RE, Marshall H, Cameron D, et al; AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15):1396-1405.
8. Brufsky A, Bundred N, Coleman R, et al; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13(5):503-514.
9. Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: ameta-analysis of individual patient data from randomized trials. Presented at: San Antonio Breast Cancer Symposium; December 2013; San Antonio, TX. Abstract S4-07.
10. Vestergaard P, Fischer L, MeleM, Mosekilde L, Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int. 2011;88(4):255-262.
11. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28(22): 3582-3590.
12. Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. 2012;131(5):717-725.
13. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010;102(5):799-802.
14. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28(22):3577-3581.
15. Chlebowski RT, Anderson GL, Gass M, et al; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
16. Liu Y, Zhao S, Chen W, et al. Bisphosphonate use and the risk of breast cancer: ameta-analysis of published literature. Clin Breast Cancer. 2012;12(4): 276-281.
17. Key TJ, Appleby PN, Reeves GK, et al; Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218-1226.
18. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90(17):1292-1299.
19. Cauley JA, Lucas FL, Kuller LH, Stone K, BrownerW, Cummings SR; Study of Osteoporotic Fractures Research Group. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med. 1999;130(4, pt 1):270-277.
20. Cummings SR, BrownerWS, Bauer D, et al; Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339(11):733-738.
21. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007; 99(15):1178-1187.
22. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96(24):1856-1865.
23. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998;83(7):2239-2243.
24. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR; The Study of Osteoporotic Fractures Research Group. Hormonal predictors of bone loss in elderly women: a prospective study. J Bone Miner Res. 1998;13(7):1167-1174.
25. Barrett-Connor E, Mueller JE, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85(1):219-223.
26. Black DM, Cummings SR, Karpf DB, et al; Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541.
27. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial.Osteoporos Int. 1993;3(suppl 3):S29-S39.
28. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082.
29. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
30. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
31. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189-2197.
32. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for theWomen's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from theWomen's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333.
33. Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335-336.
34. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116): 1151-1154.
35. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Korenman, SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, MA: Serono Symposia; 1990:211-223.
36. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47-63.
37. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117 (12):1016-1037.
38. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154 (12):1333-1339.
39. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 1997;127(7):501-508.
40. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75(6):1102-1109.
41. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med. 1990;150(12):2557-2562.
42. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151(1):75-78.
43. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 1996;28(5):1111-1118.
44. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after firstmyocardial infarction. Am J Epidemiol. 1997;145 (3):269-277.
45. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol. 1997;79(7):847-850.
46. O'Keefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol. 1997;29(1):1-5.
47. Hulley S, Grady D, Bush T, et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605-613.
48. Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298(20): 2389-2398.
49. Chlebowski RT, Col N. Bisphosphonates and breast cancer incidence and recurrence. Breast Dis. 2011;33(2):93-101.
50. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550-556.